Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan

OBJECTIVES: To assess whether switching patients with suboptimally controlled pulmonary arterial hypertension from bosentan or ambrisentan to macitentan would improve six-minute walk test (6MWT) distance and World Health Organization functional class. METHODS: This was a retrospective cohort analysi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tynan, Timothy, Hird, Kathryn, Hannon, Tara, Gabbay, Eli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567785/
https://www.ncbi.nlm.nih.gov/pubmed/30975046
http://dx.doi.org/10.1177/0300060519840130